Edison, Dainippon deepen deal with $50M up front and billions in biobucks

Japan's Dainippon Sumitomo Pharma has expanded its alliance with upstart Edison Pharmaceuticals, committing $50 million to jointly develop treatments for orphan diseases with nearly $4 billion more tied to down-the-road milestones. The deal, which builds off of a March 2013 tie-up between the two, tasks Dainippon with funding the early development of 10 jointly discovered drugs, with Edison in line for as much as $4.3 billion in sum if each therapy wins approval in North America and Japan. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.